The 85th Scientific Sessions of the American Diabetes Association (ADA 2025)
Chicago, Illinois, US 20 June 2025 - 23 June 2025
Glycaemic control in early T2D improved with novel oral GLP-1 receptor agonist
For adults with early type 2 diabetes (T2D) not adequately controlled by diet and exercise alone, treatment with the investigational small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron yields significant reductions in glycated haemoglobin levels, according to data from the phase III ACHIEVE-1 trial.
Ecnoglutide trims weight in adults with obesity
Once-a-week treatment with ecnoglutide demonstrates superiority over placebo, with sustained reductions in body weight and improvements in cardiometabolic indexes among adults with overweight or obesity, reports a study presented at ADA 2025.
Can diet drinks help with weight management?
Replacing diet beverages with water over 18 months leads to greater weight loss, improved glycaemic control, and higher diabetes remission in women with type 2 diabetes (T2D) and overweight or obesity. The benefits were sustained throughout the 18-month trial.
Novel GLP-1/GIP formula finishes strong in phase II obesity, T2D trial
In part 1 (dose ranging with and without dose escalation) of the phase II MariTide study, significant weight reduction and robust glycaemic improvement were achieved with maridebart cafraglutide (MariTide) – the first, long-acting, GIPR* antagonist and GLP-1R** agonist – in individuals with obesity or overweight and type 2 diabetes (T2D).